Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 1550 of 5804
-
Targeted drug shows promise for Hard-to-Treat lymphoma
Disease control CompletedThe goal of this clinical trial was to evaluate whether zanubrutinib can effectively treat adults with CD79B-mutant relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Participants received zanubrutinib as monotherapy, underwent regular disease assessments to evaluate …
Phase: PHASE2 • Sponsor: BeiGene • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Mind-Controlled arm training shows promise for stroke recovery
Knowledge-focused CompletedNon-invasive brain-computer interface (BCI) technology is one of the new training approaches to achieve motor restoration through a closed-loop system from brain activity through event-related desynchronization (ERD) after motor imagery (MI) or movement attempt to peripheral feed…
Phase: NA • Sponsor: The Hong Kong Polytechnic University • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:05 UTC
-
Could a common drug slow Alzheimer's? new study tests rapamycin
Disease control OngoingThis study will evaluate the safety, tolerability, and feasibility of 12 month oral rapamycin treatment in older adults with amnestic mild cognitive impairment (aMCI) and early stage Alzheimer's disease (AD).
Phase: PHASE2 • Sponsor: The University of Texas Health Science Center at San Antonio • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New oral drug shows promise for rare sun allergy conditions
Disease control Recruiting nowTo evaluate the long-term safety and tolerability of oral dersimelagon.
Phase: PHASE3 • Sponsor: Tanabe Pharma America, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Can a common steroid heal COVID-Damaged lungs?
Disease control CompletedIntroduction: The new coronavirus (SARS-CoV-2) is a virus with an intense capacity for dissemination and high mortality rate. The main cause of death is viral pneumonia, characterized as organizing pneumonia that responds to treatment with corticosteroids. After 1 month of the ac…
Phase: PHASE1 • Sponsor: University of Sao Paulo • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
New hope for tough pancreatic cancer? early trial tests immune boosts
Disease control CompletedThis trial is designed to evaluate multiple clinical hypotheses and mechanistically-defined combinations to evaluate the safety and efficacy of first-line chemo-immunotherapy combinations in participants with metastatic pancreatic ductal adenocarcinoma (mPDAC).
Phase: PHASE1 • Sponsor: Cancer Insight, LLC • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Experimental combo targets Hard-to-Treat HER2 cancers
Disease control OngoingThe dose escalation phase of this trial identifies the safety, side effects and best dose of ceralasertib (AZD6738) when given in combination with trastuzumab deruxtecan (DS-8201a) in treating patients with solid tumors that have a change (mutation) in the HER2 gene or protein an…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Real-World data shows promise for kidney cancer drug combo
Disease control CompletedThe main purpose of this study is to expand knowledge on the effectiveness of Avelumab intravenous infusion in combination with Axitinib as the first-line therapy in participants with advanced renal-cell carcinoma (aRCC) in addition to the safety and tolerability under routine co…
Sponsor: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Can your own stem cells repair MS nerve damage? new trial aims to find out
Disease control OngoingThe primary objective of the study is to investigate neuroregenerative efficacy (proof of concept) of intrathecal treatment with autologous MSCs as measured by neurophysiological parameters in patients with progressive MS. Secondary objectives are to assess neuroregenerative eff…
Phase: PHASE1, PHASE2 • Sponsor: Haukeland University Hospital • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New immunotherapy shot targets tumors with many mutations
Disease control Recruiting nowAn open, single-arm, multi-center Phase II clinical study of ENVAFOLIMAB single-agent treatment in patients with advanced solid tumors,to compare the overall response rate of TMB-high and TMB-Low,to determine the cut off value between TMB-high and TMB-Low of diagnosis device.Then…
Phase: PHASE2 • Sponsor: 3D Medicines (Sichuan) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Quick HCV treatment with peer support boosts cure rates for drug users
Disease control CompletedThis study is being done to compare two strategies to deliver HCV treatment to persons with hepatitis C virus (HCV) who also use drugs and are participating in an outpatient opioid treatment program (OTP). Participants will be randomized into one of two treatment groups: 1. Test…
Phase: NA • Sponsor: Johns Hopkins University • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New hope for liver cancer patients: which procedure best prevents dangerous rebleeding?
Disease control OngoingSP by EUS-CYA improves clinical outcomes (eg, EV rebleeding) in patients with HCC and prior EV bleeding when compared with SP by EGD-VBL
Sponsor: Chinese University of Hong Kong • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New combo therapy shows promise for Hard-to-Treat lung cancer
Disease control CompletedThis study is to evaluate the tolerability and safety of ONO-7475 in combination with osimertinib in the first-line treatment of patients with EGFR-mutated, stage IIIB/IIIC/IV or recurrent non-small cell lung cancer (NSCLC), which is unsuitable for radical irradiation.
Phase: PHASE1 • Sponsor: Ono Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New vaccine combo aims to control advanced head and neck cancer
Disease control Recruiting nowThis is a phase Ib study with a safety lead-in (n = 6 per arm) evaluating combinatorial DPV-001 + sequenced PD-1 blockade, with or without GITR agonist, in recurrent or metastatic HNSCC.
Phase: PHASE1 • Sponsor: Providence Health & Services • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Vacuum bandage may slash infection risk after GI cancer surgery
Disease control CompletedThis randomized trial will use a Negative Pressure Wound Therapy device or standard wound closure, in participants with gastrointestinal neoplasms, to measure the rate of surgical site infections
Phase: PHASE2, PHASE3 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Prostate cancer radiation gets a boost: MR-Guided trial aims to halve recurrence
Disease control OngoingOne of the usual approaches to treating intermediate-risk prostate cancer is a type of radiation therapy called SBRT (stereotactic body radiation therapy). SBRT delivers higher than standard doses of radiation over a lower number of treatment sessions. However, there is a 20% cha…
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Exercise at home may restore low blood sugar warning signs in type 1 diabetes
Symptom relief CompletedThe objective of this study is to investigate if the addition of a 12-week program of home-based high intensity interval training to a standard educational program aiming at preventing hypoglycemia episodes will restore hypoglycemia awareness in people living with type 1 diabetes…
Phase: NA • Sponsor: Institut de Recherches Cliniques de Montreal • Aim: Symptom relief
Last updated Jun 27, 2026 08:09 UTC
-
New pill shows promise for Hard-to-Treat cancers
Disease control CompletedPatients with advanced tumors diagnosed histologically or cytologically at the study center who were refractory to standard therapy or had relapsed received XNW5004 tablets
Phase: PHASE1, PHASE2 • Sponsor: Evopoint Biosciences Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
Immunotherapy duo after radiation shows promise for untreatable liver cancer
Disease control OngoingThis phase Ib trial investigates the side effects of durvalumab and tremelimumab after radioembolization (radiation particles against liver tumors) and to see how well they work in treating patients with liver cancer that cannot be removed by surgery (unresectable) and has spread…
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:10 UTC
-
Phone coaching may curb Long-Term pain after joint surgery
Symptom relief CompletedThis study will trial the impact of teaching surgical patients a pain self-management approach to compliment medical post-surgical pain management.
Phase: NA • Sponsor: VA Office of Research and Development • Aim: Symptom relief
Last updated Jul 04, 2026 00:00 UTC